Trial Profile
A retrospective, multicenter study evaluating safety and efficacy of 2D (Paritaprevir + Ombitasvir) and 3D (Parita- previr + Ombitasvir + Dasabuvir) combinations + Ribavirin (RBV) in HCV/HIV coinfected cirrhotic patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Ribavirin (Primary) ; Proton pump inhibitors; Ritonavir
- Indications Hepatitis C
- Focus Therapeutic Use
- 31 Jan 2017 New trial record